COVID-19 Drug Discovery with Qualified Cell-Based Assays for Proinflammatory Cytokines

Discover how functional cell-based assays support COVID-19 drug discovery programs, particularly in managing proinflammatory cytokines associated with high mortality rate in COVID-19 patients.

Listen to several case studies for our target-specific, MOA-reflective cell based assays for small molecules and biologic therapeutics to accelerate your drug development through QC Lot Release programs for COVID-19 research.
View Related Products: discoverx.com/interleukins